ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Regulatory News:

ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), an international company specializing in innovative molecular biology tests and global solutions for laboratories, announces that its Board of Directors, meeting on August 6, 2026, has decided to convene a shareholders' meeting on September 17, 2026, for the purpose of submitting for their approval the proposed transfer of the listing of the Company's securities from the regulated market of Euronext Paris to the Euronext Growth Paris multilateral trading facility.

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on a market more suited to its current size and stock market profile, by simplifying its operations and reducing the regulatory constraints and costs associated with its listing, while continuing to benefit from the advantages of the financial markets and the attractiveness of Euronext Growth Paris, trading market open to both professional and retail investors.